1 Patients had disease progression after ET plus CDK4/6i therapy and subsequently received systemic chemotherapy-based or ET-based therapy. The primary endpoint was progression-free survival (PFS ...

CDK4/6 inhibitor plus endocrine therapy is an active treatment option for premenopausal women with hormone receptor-positive, ...

When we bathed organ-cultured human scalp hair follicles in CDK4/6 inhibitors, the hair follicles were ... first get to grips with how exactly hair follicles responded to taxane chemotherapy, and we ...

We determine how an altered epigenetic landscape contributes to the resistance to CDK4/6 inhibitor and develop the strategies that suppress the development of resistance. 2) Overcoming chemotherapy ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

CDK4/6 inhibitors include palbociclib ... from the NIAGARA trial of Imfinzi in combination with neoadjuvant chemotherapy. "AstraZeneca reports positive outcomes from breast cancer combo therapy ...

SABCS 2024 Can AI Tool Guide CDK4/6 Inhibitor Use in Breast Cancer ... analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid progression on endocrine ...

Medscape Medical News, January 08, 2025 SABCS 2024 HRQOL the Same With CDK4/6 Inhibitors in 1st ... trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid progression ...